Hirsutism - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：28頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hirsutism - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hirsutism - Pipeline Review, H1 2014’, provides an overview of the Hirsutism’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hirsutism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hirsutism and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hirsutism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hirsutism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hirsutism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hirsutism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hirsutism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hirsutism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hirsutism - Pipeline Review, H1 2014’, provides an overview of the Hirsutism’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hirsutism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hirsutism and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hirsutism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hirsutism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hirsutism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hirsutism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hirsutism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hirsutism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Hirsutism Overview 5
Therapeutics Development 6
Pipeline Products for Hirsutism - Overview 6
Pipeline Products for Hirsutism - Comparative Analysis 7
Hirsutism - Therapeutics under Development by Companies 8
Hirsutism - Therapeutics under Investigation by Universities/Institutes 9
Hirsutism - Pipeline Products Glance 10
Early Stage Products 10
Hirsutism - Products under Development by Companies 11
Hirsutism - Products under Investigation by Universities/Institutes 12
Hirsutism - Companies Involved in Therapeutics Development 13
Hygeia Therapeutics, Inc. 13
Hirsutism - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Drug Profiles 21
HYG-440 - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HYG-430 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
HYG-420 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
HYG-410 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Hirsutism - Dormant Projects 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28
List of Tables
Number of Products under Development for Hirsutism, H1 2014 6
Number of Products under Development for Hirsutism - Comparative Analysis, H1 2014 7
Number of Products under Development by Companies, H1 2014 8
Number of Products under Investigation by Universities/Institutes, H1 2014 9
Comparative Analysis by Early Stage Development, H1 2014 10
Products under Development by Companies, H1 2014 11
Products under Investigation by Universities/Institutes, H1 2014 12
Hirsutism - Pipeline by Hygeia Therapeutics, Inc., H1 2014 13
Assessment by Monotherapy Products, H1 2014 14
Number of Products by Stage and Target, H1 2014 16
Number of Products by Stage and Mechanism of Action, H1 2014 18
Number of Products by Stage and Route of Administration, H1 2014 19
Number of Products by Stage and Molecule Type, H1 2014 20
Hirsutism - Dormant Projects, H1 2014 26
List of Figures
Number of Products under Development for Hirsutism - Comparative Analysis, H1 2014 7
Comparative Analysis by Early Stage Products, H1 2014 10
Number of Products by Top 10 Target, H1 2014 15
Number of Products by Stage and Top 10 Target, H1 2014 16
Number of Products by Top 10 Mechanism of Action, H1 2014 17
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 18
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Hirsutism Overview 5
Therapeutics Development 6
Pipeline Products for Hirsutism - Overview 6
Pipeline Products for Hirsutism - Comparative Analysis 7
Hirsutism - Therapeutics under Development by Companies 8
Hirsutism - Therapeutics under Investigation by Universities/Institutes 9
Hirsutism - Pipeline Products Glance 10
Early Stage Products 10
Hirsutism - Products under Development by Companies 11
Hirsutism - Products under Investigation by Universities/Institutes 12
Hirsutism - Companies Involved in Therapeutics Development 13
Hygeia Therapeutics, Inc. 13
Hirsutism - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Drug Profiles 21
HYG-440 - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HYG-430 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
HYG-420 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
HYG-410 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Hirsutism - Dormant Projects 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28
List of Tables
Number of Products under Development for Hirsutism, H1 2014 6
Number of Products under Development for Hirsutism - Comparative Analysis, H1 2014 7
Number of Products under Development by Companies, H1 2014 8
Number of Products under Investigation by Universities/Institutes, H1 2014 9
Comparative Analysis by Early Stage Development, H1 2014 10
Products under Development by Companies, H1 2014 11
Products under Investigation by Universities/Institutes, H1 2014 12
Hirsutism - Pipeline by Hygeia Therapeutics, Inc., H1 2014 13
Assessment by Monotherapy Products, H1 2014 14
Number of Products by Stage and Target, H1 2014 16
Number of Products by Stage and Mechanism of Action, H1 2014 18
Number of Products by Stage and Route of Administration, H1 2014 19
Number of Products by Stage and Molecule Type, H1 2014 20
Hirsutism - Dormant Projects, H1 2014 26
List of Figures
Number of Products under Development for Hirsutism - Comparative Analysis, H1 2014 7
Comparative Analysis by Early Stage Products, H1 2014 10
Number of Products by Top 10 Target, H1 2014 15
Number of Products by Stage and Top 10 Target, H1 2014 16
Number of Products by Top 10 Mechanism of Action, H1 2014 17
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 18
